Inventiva (IVA) Non-Current Receivables (2018 - 2019)
Inventiva (IVA) recorded quarterly Non-Current Receivables of $368593.6 in Q4 2019, down 3.02% quarter-over-quarter from $380085.0 in Q4 2018, and down 3.02% on a YoY basis from $380085.0 in Q4 2018.
Inventiva (IVA) Non-Current Receivables (2018 - 2019) Analysis & Trends
Inventiva's Non-Current Receivables history runs 2 years deep, the most recent figure standing at $368593.6 for Q4 2019.
- In Q4 2019, Non-Current Receivables fell 3.02% year-over-year to $368593.6; the TTM figure through Dec 2019 stood at $368593.6 (down 3.02% YoY), while the FY2019 annual figure was $368593.6, down 3.02% from the prior year.
- Non-Current Receivables was $368593.6 for Q4 2019 at Inventiva, down from $380085.0 in the prior quarter.
- In the past five years, Non-Current Receivables ranged from a high of $380085.0 in Q4 2018 to a low of $368593.6 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Inventiva | 8.78 Mn | -259.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 368,593.60 |
| Dec 31, 2018 | 380,085.01 |